Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POMTEVAR: Methylprednisolone for Post-implantation Syndrome
NCT05349071Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
01
Overview
Randomised, open-label trial of methylprednisolone injection in Post-implantation syndrome (PIS) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Rate of post-implantation syndrome at 5 days. Status: unknown.
02
Drugs
methylprednisolone injection
03
Conditions
Post-implantation syndrome (PIS)
Beyond the preview
Go deeper on NCT05349071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349071.